The importance of incorporating the patient’s voice when developing new treatments

Video

“We need to understand what the treatment [means] to them as individuals, and how they perceive the benefit of the treatment,” says Cornelia Haag, Molkenteller, MD, PhD.

In this video, Cornelia Haag-Molkenteller, MD, PhD, discusses the takeaways of the study, “Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).” Haag-Molkenteller is a chief medical officer at Urovant Sciences, Inc in Irvine, California.

Related Videos
Dr. Kyle A. Richards in an interview with Urology Times
Expert on OAB
Experts on OAB
Expert on OAB
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
stethoscope on laptop keyboard
Randie White, MD, answers a question during a Zoom video interview
Udit Singhal, MD, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.